Extracellular Vesicles as a Therapeutic Tool for Kidney Disease: Current Advances and Perspectives
Corrêa RR., Juncosa EM., Masereeuw R., Lindoso RS.
Narrative Review on Chronic Kidney Disease, Acute Kidney Injury, published in Int J Mol Sci (2021) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Int J Mol Sci (2021)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 34071399
- PMCID
- PMC8198688
- DOI
- 10.3390/ijms22115787
- Citations
- 20
Abstract (original English)
Extracellular vesicles (EVs) have been described as important mediators of cell communication, regulating several physiological processes, including tissue recovery and regeneration. In the kidneys, EVs derived from stem cells have been shown to support tissue recovery in diverse disease models and have been considered an interesting alternative to cell therapy. For this purpose, however, several challenges remain to be overcome, such as the requirement of a high number of EVs for human therapy and the need for optimization of techniques for their isolation and characterization. Moreover, the kidney's complexity and the pathological process to be treated require that EVs present a heterogeneous group of molecules to be delivered. In this review, we discuss the recent advances in the use of EVs as a therapeutic tool for kidney diseases. Moreover, we give an overview of the new technologies applied to improve EVs' efficacy, such as novel methods of EV production and isolation by means of bioreactors and microfluidics, bioengineering the EV content and the use of alternative cell sources, including kidney organoids, to support their transfer to clinical applications.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Exosomes in diabetic kidney disease: pathogenesis, biomarker discovery, and emerging therapeutics-a comprehensive systematic review
Systematic Review on Chronic Kidney Disease, published in Ren Fail (2026) — summary generated from the PubMed abstract.
- 2026
Ren Fail - Level AMeta-analysisEurope PMC
Meta-analysis study of the therapeutic impact of Mesenchymal stem cells derived exosomes for chronic kidney diseases
Meta-analysis on Chronic Kidney Disease, published in Biochem Biophys Rep (2025) — summary generated from the PubMed abstract.
- 2025
Biochem Biophys Rep2 citations - Level ASystematic ReviewPubMed
Clinical Safety and Efficacy of Allogeneic Adipose Stem Cells: A Systematic Review of the Clinical Trials.
Systematic Review with a reported sample of 953 on Osteoarthritis, Chronic Kidney Disease, Scar, Autoimmune Research, published in Int J Mol Sci (2025) — summary generated from the PubMed abstract.
- 2025
- n = 953
Int J Mol Sci2 citations - Level ASystematic ReviewEurope PMC
Worldwide hotspots and trends in stem cell therapy for kidney disease in the last decade: a bibliometric and visualization analysis from 2015 to 2024
Systematic Review on Chronic Kidney Disease, Acute Kidney Injury, published in Front Immunol (2025) — summary generated from the PubMed abstract.
- 2025
Front Immunol2 citations - Level AMeta-analysisEurope PMC
Mesenchymal Stem Cells as Anti-Inflammatory Agents in Chronic Kidney Disease: A Systematic Review and Meta-Analysis
Meta-analysis on Chronic Kidney Disease, Chronic Inflammation, published in Cells (2025) — summary generated from the PubMed abstract.
- 2025
Cells - Level AMeta-analysisEurope PMC
Protective role of exosomes in renal ischemia-reperfusion injury: a systematic review and meta-analysis
Meta-analysis on Chronic Kidney Disease, Acute Kidney Injury, published in Front Pharmacol (2025) — summary generated from the PubMed abstract.
- 2025
Front Pharmacol1 citations